Skip to main content

Table 3 Clinical parameters before and after treatment with OSCA

From: New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study

 

Before treatment (n = 87)

After treatment (n = 87)

P

Body weight (kg)

71.2 ± 13.9

70.6 ± 13.8

0.03

Systolic BP (mmHg)

131.2 ± 11.7

128.3 ± 16.1

0.06

Diastolic BP (mmHg)

79.0 ± 11.2

75.1 ± 11.2

0.01

Hemoglobin (g/dL)

12.1 ± 2.0

11.9 ± 1.9

0.04

Phosphorus (mg/dL)

3.6 ± 0.6

3.7 ± 0.7

0.07

Uric acid (mg/dL)

7.1 ± 1.8

7.3 ± 1.8

0.05

BUN (mg/dL)

35.2 ± 12.7

36.1 ± 12.7

0.37

Serum creatinine (mg/dL)

2.5 ± 0.8

2.6 ± 0.9

0.06

eGFR by Creatinine (mL/min/1.73m2)

31.7 ± 11.3

32.0 ± 13.1

0.57

Serum albumin (g/dL)

3.9 ± 0.6

3.9 ± 0.5

0.43

  1. The paired t-tests were performed to compare the two groups
  2. Abbreviation: OSCA oral spherical carbon adsorbent, BMI body mass index, BP blood pressure, CKD chronic kidney disease, eGFR estimated glomerular filtration rate
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us